Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/157937
Title: Antiapoptotic BCL-2 proteins determine Sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma
Author: Tutusaus, Anna
Stefanovic, Milica
Boix, Loreto
Cucarull, Blanca
Zamora, Aynara
Blasco, Laura
García de Frutos, Pablo
Reig, María
Fernández-Checa Torres, José Carlos
Marí García, Montserrat
Colell Riera, Anna
Bruix Tudó, Jordi
Morales Muñoz, Albert
Keywords: Càncer de fetge
Inhibidors enzimàtics
Tractament adjuvant del càncer
Liver cancer
Enzyme inhibitors
Adjuvant treatment of cancer
Issue Date: 30-Mar-2018
Publisher: Impact Journals
Abstract: Sorafenib, systemic treatment for advanced hepatocellular carcinoma (HCC), and regorafenib, novel second line treatment after sorafenib failure, have efficacy limited by evasive mechanisms of acquired-drug resistance. BCL-2 proteins participate in the response to tyrosine kinase inhibitors; however, their role in HCC therapy with sorafenib/regorafenib remains uncertain. BH3-mimetic ABT-263 (navitoclax) enhanced sorafenib activity, inducing cell death via a mitochondrial caspase-dependent mechanism, after BCL-xL/BCL-2 inhibition. Sorafenib-resistant hepatoma cells (HepG2R and Hep3BR) exhibited altered mRNA expression of BCL-2 and other anti-apoptotic family members, such as MCL-1, priming drug-resistant cancer cells to death by BH3-mimetics. ABT-263 restored sorafenib efficacy in sorafenib-resistant cell lines and HCC mouse models. Moreover, in mice xenografts from patient-derived BCLC9 cells, better tumor response to sorafenib was associated to higher changes in the BCL-2 mRNA pattern. HCC non-treated patients displayed altered BCL-2, MCL-1 and BCL-xL mRNA levels respect to adjacent non-tumoral biopsies and an increased BCL-2/MCL-1 ratio, predictive of navitoclax efficacy. Moreover, regorafenib administration also modified the BCL-2/MCL-1 ratio and navitoclax sensitized hepatoma cells to regorafenib by a mitochondrial caspase-dependent mechanism. In conclusion, sorafenib/regorafenib response is determined by BCL-2 proteins, while increased BCL-2/MCL-1 ratio in HCC sensitizes drug resistant-tumors against ABT-263 co-administration. Thus, changes in the BCL-2 profile, altered in HCC patients, could help to follow-up sorafenib efficacy, allowing patient selection for combined therapy with BH3-mimetics or early switch them to second line therapy.
Note: Reproducció del document publicat a: https://doi.org/10.18632/oncotarget.24673
It is part of: Oncotarget, 2018, vol. 9, num. 24, p. 16701-16717
URI: http://hdl.handle.net/2445/157937
Related resource: https://doi.org/10.18632/oncotarget.24673
ISSN: 1949-2553
Appears in Collections:Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
692345.pdf10.45 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons